Last reviewed · How we verify

NCT07387679

Myo-inositol Versus Metformin in Patients With Polycystic Ovarian Syndrome to Treat Obesity

Completed NA Last updated 4 February 2026
What this trial tests

NA trial testing Myo-inositol in Polycystic Ovarian Syndrome in 60 participants. Completed in 28 May 2025.

Timeline
29 November 2024
Primary endpoint
28 May 2025
28 May 2025

Quick facts

Lead sponsorMuhammad Aamir Latif
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment60
Start date29 November 2024
Primary completion28 May 2025
Estimated completion28 May 2025
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Muhammad Aamir Latif — full company profile →

Who can join

Adults 18 to 45, female only, with Polycystic Ovarian Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There are considerable gaps in the comparative effectiveness and tolerability of myo-inositol and metformin for treating obesity in patients with polycystic ovarian syndrome (PCOS). The current study aimed to give insights comparing myo-inositol versus metformin for treating obesity in patients with PCOS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Myo-inositol

Trials testing the same drug.

Other recruiting trials for Polycystic Ovarian Syndrome

Currently open trials in the same condition.

Other Muhammad Aamir Latif trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07387679.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing